- Meta-analysis suggests blinatumomab, a bispecific T-cell engager antibody, is safe, effective in relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL).
- The response rate was higher in patients with ALL with lower tumor load.
Why this matters
- Patients with relapsed/refractory ALL or NHL have a poor prognosis.
- Meta-analysis of 8 studies including 729 patients with refractory/ relapsed ALL (n=628) and NHL (n=101).
- Funding: The National Key Basic Research Program of China.
- Blinatumomab achieved pooled complete remission (CR) rate of
- 45% in patients with ALL (effect size [ES], 0.45; 95% CI, 0.37-0.53) and
- 20% in patients with NHL (ES, 0.20; 95% CI, 0.12-0.27).
- CR rate was higher in patients with bone marrow blast
- History of allogenic-hematopoietic stem cell transplantation did not affect CR rate.
- 23.6% of patients with ALL and 2.6% with NHL proceeded to allogeneic HSCT after blinatumomab treatment.
- In patients with ALL, the minimal residual disease rate was 42% (ES, 0.42; 95% CI, 0.29-0.54).
- Pooled rate of grade ≥3 cytokine release syndrome was 4% and that of neurological events was 12%.
- Small sample size, high heterogeneity.
- Random effects model may minimize the inherent variances.